How Verzenio Works for Metastatic Breast Cancer

Verzenio (abemaciclib) is a prescription medication used to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant.

Verzenio belongs to a class of medications known as cyclin-dependent kinase (CDK) inhibitors, which work by blocking the activity of certain proteins involved in cell division and growth. This can help to slow down or stop the growth of cancer cells.

Verzenio is typically taken orally once twice daily with food. The recommended starting dose is 150 mg. If this dose is well-tolerated, the dose may be increased to 200 mg twice daily.

Verzenio can cause certain side effects, including diarrhea, nausea, vomiting, fatigue, hair loss, and decreased appetite. These side effects are generally mild to moderate in severity and can be managed with supportive care measures.

Verzenio can also lead to a decrease in white blood cell counts, which can increase the risk of infections. Regular blood tests will be done to monitor your blood counts while you are taking Verzenio.

It is important to follow the dosing instructions provided by your doctor and to attend all scheduled follow-up appointments. Verzenio can interact with certain other medications, so it is important to inform your doctor about all medications you are taking, including prescription and over-the-counter drugs, vitamins, and herbal supplements.

Verzenio is a powerful medication that can be effective in treating metastatic breast cancer. However, it is important to be aware of the potential side effects and to work closely with your doctor to manage these effects and ensure the safety and effectiveness of your treatment.